Brown Advisory
CHRS icon

Brown Advisory’s Coherus Oncology CHRS Stock Holding History

Brown Advisory’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-277,471
Closed -$4.05M – 1085
2021
Q1 		$4.05M Buy
277,471
+257,099
+1,262% +$4.37M 0.01% 499
2020
Q4 		$354K Sell
20,372
-835,296
-98% -$14.9M ﹤0.01% 847
2020
Q3 		$15.7M Buy
855,668
+49,554
+6% +$922K 0.03% 259
2020
Q2 		$14.4M Buy
806,114
+44,962
+6% +$761K 0.03% 262
2020
Q1 		$12.3M Buy
761,152
+7,816
+1% +$144K 0.04% 251
2019
Q4 		$13.6M Buy
753,336
+23,538
+3% +$434K 0.03% 288
2019
Q3 		$14.8M Buy
729,798
+73,343
+11% +$1.47M 0.04% 269
2019
Q2 		$14.5M Buy
656,455
+3,061
+0.5% +$53.2K 0.04% 282
2019
Q1 		$8.91M Sell
653,394
-17,709
-3% -$236K 0.03% 362
2018
Q4 		$6.07M Buy
671,103
+11,837
+2% +$137K 0.02% 390
2018
Q3 		$10.9M Buy
659,266
+25,222
+4% +$447K 0.03% 321
2018
Q2 		$8.88M Sell
634,044
-3,933
-0.6% -$56.3K 0.03% 353
2018
Q1 		$7.05M Buy
637,977
+4,942
+0.8% +$54.1K 0.02% 350
2017
Q4 		$5.57M Buy
633,035
+39,014
+7% +$418K 0.02% 390
2017
Q3 		$7.93M Buy
594,021
+31,211
+6% +$413K 0.03% 332
2017
Q2 		$8.08M Buy
562,810
+111,274
+25% +$2.14M 0.02% 341
2017
Q1 		$9.55M Buy
451,536
+115,536
+34% +$2.84M 0.03% 301
2016
Q4 		$9.46M Buy
336,000
+13,098
+4% +$367K 0.03% 295
2016
Q3 		$8.65M Buy
322,902
+25,152
+8% +$686K 0.03% 295
2016
Q2 		$5.03M Buy
297,750
+55,728
+23% +$1.05M 0.02% 358
2016
Q1 		$5.14M Buy
242,022
+41,104
+20% +$673K 0.02% 356
2015
Q4 		$4.61M Buy
200,918
+5,937
+3% +$153K 0.02% 376
2015
Q3 		$3.91M Buy
194,981
+15,099
+8% +$459K 0.01% 393
2015
Q2 		$5.2M Sell
179,882
-41,631
-19% -$1.05M 0.02% 341
2015
Q1 		$6.77M Sell
221,513
-2,387
-1% -$61.7K 0.02% 320
2014
Q4 		$3.65M Buy
+223,900
New +$3.16M 0.01% 390

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Brown Advisory's CHRS Position: Q2 2021 in Review

Brown Advisory sold out of Coherus Oncology (CHRS) in Q2 2021, closing a stake of 277,471 shares — an estimated $4.05M sold.

Brown Advisory first reported a position in CHRS in Q4 2014 and held it in 26 quarters. The position peaked at $15.7M in Q3 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

  • Brown Advisory reported no remaining Coherus Oncology position as of Q2 2021 after selling out during the quarter.
  • Brown Advisory sold 277,471 Coherus Oncology shares in Q2 2021, an estimated $4.05M.
  • Brown Advisory first reported a position in Coherus Oncology in Q4 2014 and held it in 26 quarters.
  • Brown Advisory's Coherus Oncology position peaked at $15.7M in Q3 2020.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on Brown Advisory's 13F filing for Q2 2021, filed 29 Jul 2021.